1. Home
  2. BARK vs ADCT Comparison

BARK vs ADCT Comparison

Compare BARK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BARK Inc.

BARK

BARK Inc.

HOLD

Current Price

$0.54

Market Cap

115.2M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.65

Market Cap

483.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BARK
ADCT
Founded
2011
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.2M
483.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BARK
ADCT
Price
$0.54
$3.65
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$2.50
$7.60
AVG Volume (30 Days)
921.1K
1.2M
Earning Date
02-04-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$451,690,000.00
$75,209,000.00
Revenue This Year
N/A
$10.36
Revenue Next Year
$5.02
$3.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.35
52 Week Low
$0.53
$1.05
52 Week High
$2.32
$4.80

Technical Indicators

Market Signals
Indicator
BARK
ADCT
Relative Strength Index (RSI) 30.69 47.55
Support Level $0.55 $3.38
Resistance Level $0.62 $3.66
Average True Range (ATR) 0.04 0.20
MACD -0.00 0.01
Stochastic Oscillator 5.18 45.39

Price Performance

Historical Comparison
BARK
ADCT

About BARK BARK Inc.

BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: